Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of extracorporeal cytokine absorber and CRRT on plasma levels of meropenem, linezolid and anidulafungin
DRKS00023684Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2023
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of meropenem, linezolid and anidulafungin in sepsis and septic shock (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Impact of cytokine absorber and CRRT on meropenem plasma levels, Impact of cytokine absorber and CRRT on linezolid plasma levels and 1 more. Started Jan 2023; status: completed.
02
Drugs
meropenemlinezolidanidulafungin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on DRKS00023684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023684.